Change?Three high-quality new board members, New COO, Boston Group at 40%+, Boston Group taking an active role, Williams and Goldstein changing chairs is not the final move, expect new Chief Medical Officer and new CEO, Company targeting a $650 market cap of a comparable biopharma peer, not thinking of financing until mid to late 2022, preparation has begun for huge document delivery for FDA clinical trial filing, hoping for a possible live conference call for Q3, and much more. News flow, NASDAQ listing and new analyst coverage are all potential catalysts. It is hard to say what specifically will be "the catalyst" for a breakout. Now at 1.3M shares, confidence inspired by Boston billionaires going all in with Promis and making the necessary moves and changes. Stay positive-this is going to pay off.